Włochy - włoski - AIFA (Agenzia Italiana del Farmaco)

g.l. pharma gmbh - lacosamide - lacosamide

Unia Europejska - włoski - EMA (European Medicines Agency)

ucb pharma sa - lacosamide - epilessia - antiepilettici, - vimpat è indicato come monoterapia e terapia aggiuntiva nel trattamento delle crisi ad esordio parziale con o senza generalizzazione secondaria negli adulti, negli adolescenti e nei bambini dai 4 anni di età con epilessia.

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - lacosamidum - compresse rivestite con film - lacosamidum 50 mg, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, cellulosum microcristallinum silicificatum, crospovidonum, magnesii stearas, hydroxypropylcellulosum, pellicule: poly(alcohol vinylicus), talcum, macrogolum 3350, e 132, e 171, e 172 (rubrum), e 172 (nigrum) pro compresso obducto. - aed - synthetika

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - lacosamidum - compresse rivestite con film - lacosamidum 100 mg, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, cellulosum microcristallinum silicificatum, crospovidonum, magnesii stearas, hydroxypropylcellulosum, pellicule: poly(alcohol vinylicus), talcum, macrogolum 3350, e 171, e 172 (flavum) pro compresso obducto. - aed - synthetika

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - lacosamidum - compresse rivestite con film - lacosamidum 150 mg, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, cellulosum microcristallinum silicificatum, crospovidonum, magnesii stearas, hydroxypropylcellulosum, pellicule: poly(alcohol vinylicus), talcum, macrogolum 3350, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum) pro compresso obducto. - aed - synthetika

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - lacosamidum - compresse rivestite con film - lacosamidum 200 mg, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, cellulosum microcristallinum silicificatum, crospovidonum, magnesii stearas, hydroxypropylcellulosum, pellicule: poly(alcohol vinylicus), talcum, macrogolum 3350, e 132, e 171 pro compresso obducto. - aed - synthetika

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - lacosamidum - sciroppo - lacosamidum 10 mg, glycerolum 85 mg, carmellosum natricum, sorbitolum liquidum cristallisabile 266.67 mg corresp. sorbitolum 187 mg, macrogolum 4000, natrii chloridum, acidum citricum, aqua purificata, aromatica, aspartamum 0.032 mg, acesulfamum kalicum, e 219 2.6 mg ad solutionem pro 1 ml corresp. natrium 1.49 mg. - aed - synthetika

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - lacosamidum - soluzione versare perfusione - lacosamidum 10 mg, natrii chloridum, acidum hydrochloridum, aqua ad iniectabile ad solutionem pro 1 ml corresp. natrium 3.0 mg. - aed - synthetika

Unia Europejska - włoski - EMA (European Medicines Agency)

accord healthcare s.l.u. - lacosamide - epilessia - antiepilettici, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Włochy - włoski - AIFA (Agenzia Italiana del Farmaco)

so.se.pharm s.r.l. societa' di servizio per l'industria farmaceutica ed affini - lacosamide - lacosamide